Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses

Next Previous
X
Search
Trial Profile

Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide (Primary) ; Antiretrovirals
  • Indications HIV-1 infections
  • Focus Pharmacodynamics
  • Acronyms EARLIER

    • Most Recent Events

    • 02 Feb 2023 Planned End Date changed from 8 Sep 2023 to 30 Apr 2025.
    • 22 Jan 2021 Planned End Date changed from 17 May 2021 to 8 Sep 2023.
    • 11 Mar 2020 Results (n=174) evaluating Novel Criteria for Diagnosing Acute Hiv in a Multinational Art-Initiation Study, presented at the 27th Conference on Retroviruses and Opportunistic Infections

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top